Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Pharvaris' innovative approach to treating hereditary angioedema (HAE) with deucrictibant. Read here for an investment ...

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and gene therapy.

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

Surgery and ablation for small liver tumors led to similar outcomes in a large study from Japan. Data from a randomized trial showed a 5-year overall survival (OS) of 74.6% with surgery and 70.4% with ...

U.S. Market Leads with 74% Share in 2023 Valued at USD 2.71 Billion, Driven by Biotech Innovation, Favorable FDA Approvals, and Rising Chronic Disease Incidence.Austin, July 18, 2025 (GLOBE NEWSWIRE) ...

Three patients with a muscle-wasting disease died from liver failure after taking the therapy, Ele­vidys, or a similar ...

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.

The elritercept Phase 3 RENEW clinical trial (NCT06499285) is a global, randomized, double-blind, placebo-controlled trial in adults with transfusion-dependent anemia with very low, low, and ...